Elicio Therapeutics Inc. (NASDAQ:ELTX) — Market Cap & Net Worth
Market Cap & Net Worth: Elicio Therapeutics Inc. (ELTX)
Elicio Therapeutics Inc. (NASDAQ:ELTX) has a market capitalization of $49.41 Million ($49.41 Million) as of September 25, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21997 globally and #4900 in its home market, demonstrating a -10.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elicio Therapeutics Inc.'s stock price $1.88 by its total outstanding shares 26281882 (26.28 Million). Also see Elicio Therapeutics Inc. (ELTX) total assets for a full breakdown of the balance sheet.
Elicio Therapeutics Inc. Market Cap History: 2021 to 2026
Elicio Therapeutics Inc.'s market capitalization history from 2021 to 2026. Data shows change from $762.17 Million to $49.41 Million (-55.04% CAGR). Also see Elicio Therapeutics Inc. (ELTX) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Elicio Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.00% | #632 of 976 |
|
NASDAQ Composite
IXIC
|
$42.16 Trillion | 0.00% | #2092 of 3165 |
Weight: Elicio Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elicio Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elicio Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ELTX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
26.92x
Elicio Therapeutics Inc.'s market cap is 26.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $762.17 Million | $28.31 Million | -$26.40 Million | 26.92x | N/A |
Competitor Companies of ELTX by Market Capitalization
Companies near Elicio Therapeutics Inc. in the global market cap rankings as of September 25, 2026. Review Elicio Therapeutics Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Elicio Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #333 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $61.49 Billion USD ( AU$86.90 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $522.38 |
| #333 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $796.02 |
| #450 | CSL Ltd | AU:CSL | $61.49 Billion | AU$179.12 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $194.82 |
Elicio Therapeutics Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Elicio Therapeutics Inc.'s market cap moved from $762.17 Million to $ 49.41 Million, with a yearly change of -55.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.41 Million | -76.38% |
| 2025 | $209.20 Million | +56.08% |
| 2024 | $134.04 Million | -38.85% |
| 2023 | $219.19 Million | +2.71% |
| 2022 | $213.41 Million | -72.00% |
| 2021 | $762.17 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 25th, 2026 the market cap of Elicio Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.41 Million USD |
| MoneyControl | $49.41 Million USD |
| MarketWatch | $49.41 Million USD |
| marketcap.company | $49.41 Million USD |
| Reuters | $49.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more